The manufacturer is called Nostrum Laboratories, and the drug for which it hiked the price—by more than 400 percent—is called nitrofurantoin. It’s a name that probably means nothing to most, but is precious to the 6 to 8 million Americans who get urinary tract infections every year. Nitrofurantoin treats bladder infections, and Nostrum’s version is a liquid, used for children, elderly patients, and anyone who can’t swallow a pill.
The medical community is furious: Two professional societies, the Infectious Diseases Society of America and the HIV Medicine Association, called the hike “cynical opportunism” and “opportunistic greed in its most indefensible form.” The company CEO has been unimpressed, telling the Financial Times: “We have to make money when we can.”
…continue reading ‘The Case for Expensive Antibiotics’
Image By User:Kristoferb, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=23427514
Be the first to like.
WIRED